Figure 3.

4Mu therapy increases the homing of specific antitumor T lymphocytes into CT26 s.c. tumors and inhibits tumor growth. (a) In vivo tracking of CD3⁺DiR⁺-specific T lymphocytes. Fourteen days after CT26 cells inoculation, tumor-bearing mice previously treated with 4Mu or saline during 7 days (n = 4/group) were intravenously injected with CD3⁺DiR⁺ cells (1 × 10⁶). DiR fluorescence quantification was performed using bioluminescence imaging 24 hours after T-cells injection. Images represent the radiant efficiency and results were expressed as total flux of radiant efficiency. *P < 0.05: control versus 4Mu; Mann-Whitney test. Experiments are shown as the representative of three independent assays. (b) Antitumoral effect of adoptive T cells therapy on untreated or 4Mu-treated tumor-bearing mice. Administration of 4Mu plus adoptive transfer of specific T cells induced a significant inhibition of tumor growth in comparison with each therapy alone. Bars represent the average of measures of each group (n = 8/group) ± SEM; *P < 0.05. Kruskal-Wallis test. Experiments are shown as the representative of two independent assays.